Reports indicate that Apple (AAPL, Financial) is making strides in the brain-computer interface (BCI) sector, partnering with Synchron (SNCR) to develop a cutting-edge technology aimed at transforming human-device interactions. This innovation allows users to control iPhones and other Apple devices using only their thoughts through next-generation brain implants that read neural signals.
The technology primarily assists individuals with limited hand use due to conditions such as spinal cord injuries or ALS. Synchron is developing an implant named Stentrode, which reads brain signals from the motor cortex and translates them into screen icon selections using Apple's "Switch Control." Stentrode has successfully completed clinical trials, and the two companies are working on new standards for Apple devices.
While BCI technology shows promise, Apple plans to release Synchron's software standard to developers later this year. Despite current limitations, including challenges in simulating touchscreen navigation, Synchron has implanted Stentrode in 10 patients since 2019. Morgan Stanley estimates that about 150,000 Americans could be early adopters of BCI technology. The commercial launch is anticipated by 2030, though Synchron aims for earlier approval. Apple's ongoing efforts in accessibility technologies remain noteworthy, reflected in its earlier innovations like hearing aid connectivity software.
